Comparative Pharmacology
Head-to-head clinical analysis: CYCLOCORT versus MICORT HC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLOCORT versus MICORT HC.
CYCLOCORT vs MICORT-HC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive actions. Suppresses cytokine production, inhibits phospholipase A2, and reduces prostaglandin synthesis.
Topical corticosteroid that binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine release, thereby exerting anti-inflammatory, antipruritic, and vasoconstrictive effects.
Apply a thin film topically to affected area twice daily (morning and evening). Not for ophthalmic use.
Topical: Apply a thin film to affected area 2-4 times daily. Rectal: Insert one suppository (25 mg) rectally twice daily (morning and evening) for 2-3 weeks, then taper as needed.
None Documented
None Documented
3.5 hours (terminal); clinical effect duration longer due to tissue binding.
Terminal elimination half-life is 1.5-2.5 hours; clinical duration of action is longer due to genomic effects lasting 8-12 hours.
Primarily hepatic metabolism; inactive metabolites excreted renally (<1% unchanged) and in feces (biliary).
Renal (approximately 70% as inactive metabolites, <5% unchanged); fecal (approximately 30%)
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid